TABLE 1.
Patient demographics.
| PSD patients | PSND patients | P-value | |
| Sample size | 31 | 23 | |
| Age | 64 ± 10 | 67 ± 12 | 0.424 |
| Male gender (%) | 55 | 65 | 0.443 |
| Hamilton depression rating scale | 8.5 ± 1.8 | 3.7 ± 0.8 | < 0.001 |
| Prevalence (%) | |||
| Diabetes mellitus | 16 | 17 | 0.866 |
| Hypertension | 52 | 48 | 0.643 |
| Ischemic heart disease | 6 | 9 | 0.597 |
| Hyperlipidemia | 32 | 29 | 0.801 |
| Stroke classification (%) | 0.617 | ||
| Large artery antherosclerosis | 35 | 35 | |
| Small vessel disease | 16 | 9 | |
| Cardioembolism | 16 | 26 | |
| Undetermined | 33 | 30 | |
| Infarct location (%) | |||
| Basal ganglia | 54 | 68 | 0.375 |
| Brain stem | 29 | 11 | 0.274 |
| Cerebellum | 0 | 11 | 0.410 |
| Frontal lobe | 10 | 16 | 1 |
| Parietal lobe | 6 | 11 | 1 |
| Temporal lobe | 6 | 5 | 1 |
| Occipital lobe | 6 | 5 | 1 |
| Infarct size (cm3) | 5.6 ± 10.1 | 4.8 ± 9.8 | 0.793 |
| Infarct sides (L/R) | 17/14 | 12/11 | 0.650 |
| Smoking | 26 | 39 | 0.215 |
| Antiplatelets | 19 | 30 | 0.186 |
| Lipid-lowering drugs | 30 | 26 | 0.427 |
| Serum total cholesterol (mmol/L) | 4.8 ± 1.3 | 4.4 ± 1.5 | 0.376 |
| Hemoglobin (g/dL) | 13.9 ± 1.4 | 13.3 ± 1.6 | 0.176 |
| Serum glucose level (mmol/L) | 6.9 ± 3.2 | 5.8 ± 1.5 | 0.153 |
PSD, post-stroke depression; PSND, post-stroke non-depression.